1021913-03-0Relevant articles and documents
CHEMICAL COMPOUNDS
-
Paragraph 0348; 0936-0937, (2019/06/20)
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
AMINO-QUINOLINES AS KINASE INHIBITORS
-
, (2018/06/22)
Disclosed are compounds having the formula:wherein R 1 , R 2 , R 3 and Z are as defined herein, and methods of making and using the same.
AMINO-QUINOLINES AS KINASE INHIBITORS
-
, (2018/05/15)
Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
COMBINATION THERAPIES FOR TREATMENT OF CANCER
-
, (2016/04/09)
Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.
AMINO-QUINOLINES AS KINASE INHIBITORS
-
, (2016/10/31)
Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
INHIBITORS OF KRAS G12C
-
, (2015/04/28)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Design, synthesis, and evaluation of novel 3,6-diaryl-4- aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2
Wolkenberg, Scott E.,Zhao, Zhijian,Thut, Catherine,Maxwell, Jill W.,McDonald, Terrence P.,Kinose, Fumi,Reilly, Michael,Lindsley, Craig W.,Hartman, George D.
, p. 2351 - 2358 (2011/06/17)
Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.
Controlled derivatization of polyhalogenated quinolines utilizing selective cross-coupling reactions
Brad Nolt,Zhao, Zhijian,Wolkenberg, Scott E.
, p. 3137 - 3141 (2008/09/20)
Straightforward procedures for the derivatization of tri- and tetrahalogenated quinolines utilizing sequential selective Pd-catalyzed cross-coupling reactions are described. Taking advantage of intrinsic halide reactivity, substrate control, and appropria
SOMATOSTATIN AGONISTS
-
Page/Page column 19; 20, (2008/12/05)
This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy,